

Boston Scientific

Boston Scientific Comments on U.K. Court Decision on Angiotech Patent

PRNewswire-FirstCall

NATICK, Mass.

(NYSE:BSX)

NATICK, Mass., Jan. 16 /[PRNewswire-FirstCall](#)/ -- Boston Scientific Corporation (NYSE: BSX) commented on a decision today by the U.K. Court of Appeal that affirmed an earlier ruling by a lower court to revoke the U.K. version of a European paclitaxel stent patent owned by Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) (TSX: ANP). The European patent -- the Netherlands version of which was upheld by a Dutch court in May, 2006 -- remains valid and enforceable in all other designated European jurisdictions. The European patent is part of a worldwide patent portfolio exclusively licensed to Boston Scientific.

"While we are disappointed with the Court's decision, we are confident in the strength and validity of Angiotech's patent portfolio elsewhere around the world," said Boston Scientific spokesman Paul Donovan.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

<http://www.bostonscientific.com/>.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Dan Brennan
508-650-8538 (office)
617-459-2703 (mobile)
Investor Relations
Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Paul Donovan, Media Relations, +1-508-650-8541, or mobile, +1-508-667-5165, or Dan Brennan, Investor Relations, +1-508-650-8538, or mobile, +1-617-459-2703, both of Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

<https://news.bostonscientific.com/news-releases?item=58929>